TrialCurveNORA (final overall survival): reconstructed Kaplan–Meier curves
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. Curves rebuilt as patient-level data (Guyot 2012) and checked against the statistics printed on the figure.
| Publication | eClinicalMedicine. 2024 May 7;72:102629. doi: 10.1016/j.eclinm.2024.102629 |
|---|---|
| DOI | 10.1016/j.eclinm.2024.102629 |
| Registry | NCT03705156 |
| Phase | Phase 3 |
| Conditions | Platinum-sensitive Relapsed Ovarian Cancer |
| Interventions | ZL-2306(nirapairb), Placebos |
| Sponsor | Zai Lab (Shanghai) Co., Ltd. |
| Enrolment | 265 |
| Source licence | Figure published under CC BY 4.0 |
Overall survival — Overall population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 51.5 months; Placebo 47.6 months. Survival at 18 months: Niraparib 89%; Placebo 83%. Hazard ratio Niraparib vs Placebo 0.88 (95% CI 0.62–1.26).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 177 | 94 | 51.5 |
| Placebo | 88 | 45 | 47.6 |
- Niraparib vs Placebo: reconstructed HR 0.88 (95% CI 0.62–1.26)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 97.1% | 91.6% |
| 18 mo | 89.0% | 82.9% |
| 24 mo | 83.2% | 75.3% |
| 36 mo | 65.1% | 57.2% |
| 48 mo | 52.8% | 48.9% |
| 60 mo | 42.6% | — |
Checks against the published figure
- Niraparib median: printed 51.5, reconstructed 51.5 pass
- Placebo median: printed 47.6, reconstructed 47.6 pass
- Niraparib events: printed 93, reconstructed 94 pass
- Niraparib n: printed 177, reconstructed 177 pass
- Placebo events: printed 45, reconstructed 45 pass
- Placebo n: printed 88, reconstructed 88 pass
- hazard ratio (direction inferred): printed 0.86, reconstructed 0.879 pass
Overall survival — Patients with germline BRCA mutations
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 55.5 months; Placebo 47.6 months. Survival at 18 months: Niraparib 94%; Placebo 87%. Hazard ratio Niraparib vs Placebo 0.88 (95% CI 0.48–1.60).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 65 | 33 | 55.5 |
| Placebo | 35 | 16 | 47.6 |
- Niraparib vs Placebo: reconstructed HR 0.88 (95% CI 0.48–1.60)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 98.4% | 93.9% |
| 18 mo | 93.7% | 87.2% |
| 24 mo | 85.7% | 83.9% |
| 36 mo | 64.4% | 58.0% |
| 48 mo | 57.6% | 46.4% |
| 60 mo | 42.7% | 41.3% |
Checks against the published figure
- Niraparib median: printed 56, reconstructed 55.5 pass
- Placebo median: printed 47.6, reconstructed 47.6 pass
- Niraparib events: printed 33, reconstructed 33 pass
- Niraparib n: printed 65, reconstructed 65 pass
- Placebo events: printed 16, reconstructed 16 pass
- Placebo n: printed 35, reconstructed 35 pass
- hazard ratio (direction inferred): printed 0.86, reconstructed 0.879 pass
Overall survival — Patients without germline BRCA mutations
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 46.5 months; Placebo 46.9 months. Survival at 18 months: Niraparib 86%; Placebo 80%. Hazard ratio Niraparib vs Placebo 0.87 (95% CI 0.56–1.36).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 112 | 61 | 46.5 |
| Placebo | 53 | 29 | 46.9 |
- Niraparib vs Placebo: reconstructed HR 0.87 (95% CI 0.56–1.36)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 100.0% | 100.0% |
| 12 mo | 96.4% | 90.2% |
| 18 mo | 86.3% | 80.2% |
| 24 mo | 81.7% | 70.2% |
| 36 mo | 65.6% | 56.0% |
| 48 mo | 49.9% | 49.5% |
| 60 mo | 40.8% | — |
Checks against the published figure
- Niraparib median: printed 46.5, reconstructed 46.5 pass
- Placebo median: printed 46.9, reconstructed 46.9 pass
- Niraparib events: printed 60, reconstructed 61 pass
- Niraparib n: printed 112, reconstructed 112 pass
- Placebo events: printed 29, reconstructed 29 pass
- Placebo n: printed 53, reconstructed 53 pass
- hazard ratio (direction inferred): printed 0.87, reconstructed 0.872 pass
Chemotherapy-free interval — Overall population
From figure panel A · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 19.6 months; Placebo 10.2 months. Survival at 18 months: Niraparib 52%; Placebo 25%. Hazard ratio Niraparib vs Placebo 0.51 (95% CI 0.38–0.69).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 177 | 123 | 19.6 |
| Placebo | 88 | 69 | 10.2 |
- Niraparib vs Placebo: reconstructed HR 0.51 (95% CI 0.38–0.69)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 94.9% | 80.7% |
| 12 mo | 69.3% | 37.2% |
| 18 mo | 52.0% | 25.2% |
| 24 mo | 42.5% | 19.8% |
| 36 mo | 36.2% | 18.4% |
| 48 mo | 32.2% | 15.6% |
| 60 mo | 27.0% | 15.6% |
Checks against the published figure
- Niraparib median: printed 19.7, reconstructed 19.6 pass
- Placebo median: printed 10.1, reconstructed 10.2 pass
- Niraparib events: printed 122, reconstructed 123 pass
- Niraparib n: printed 177, reconstructed 177 pass
- Placebo events: printed 68, reconstructed 69 pass
- Placebo n: printed 88, reconstructed 88 pass
- hazard ratio (direction inferred): printed 0.47, reconstructed 0.513 pass
Time to first subsequent anti-cancer therapy — Overall population
From figure panel B · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 16.7 months; Placebo 7.7 months. Survival at 18 months: Niraparib 47%; Placebo 16%. Hazard ratio Niraparib vs Placebo 0.42 (95% CI 0.31–0.55).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 177 | 138 | 16.7 |
| Placebo | 88 | 80 | 7.7 |
- Niraparib vs Placebo: reconstructed HR 0.42 (95% CI 0.31–0.55)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 86.4% | 64.5% |
| 12 mo | 61.0% | 22.7% |
| 18 mo | 47.3% | 16.4% |
| 24 mo | 37.9% | 13.9% |
| 36 mo | 30.2% | 6.3% |
| 48 mo | 25.4% | 5.0% |
| 60 mo | 20.4% | 5.0% |
Checks against the published figure
- Niraparib median: printed 16.6, reconstructed 16.7 pass
- Placebo median: printed 7.7, reconstructed 7.68 pass
- Niraparib events: printed 138, reconstructed 138 pass
- Niraparib n: printed 177, reconstructed 177 pass
- Placebo events: printed 79, reconstructed 80 pass
- Placebo n: printed 88, reconstructed 88 pass
- hazard ratio (direction inferred): printed 0.39, reconstructed 0.417 pass
Progression-free survival 2 — Overall population
From figure panel C · validated against the values printed on the figure · curve source: pixel measurement confirmed by vision model
Reconstructed from the published curve. Median: Niraparib 27.6 months; Placebo 17.2 months. Survival at 18 months: Niraparib 74%; Placebo 44%. Hazard ratio Niraparib vs Placebo 0.53 (95% CI 0.39–0.72).
| Arm | N | Events | Median (Months) |
|---|---|---|---|
| Niraparib | 177 | 112 | 27.6 |
| Placebo | 88 | 64 | 17.2 |
- Niraparib vs Placebo: reconstructed HR 0.53 (95% CI 0.39–0.72)
Landmark survival (reconstructed)
| Time | Niraparib | Placebo |
|---|---|---|
| 6 mo | 98.3% | 92.9% |
| 12 mo | 84.3% | 67.8% |
| 18 mo | 73.7% | 44.3% |
| 24 mo | 53.0% | 32.9% |
| 36 mo | 41.9% | 17.2% |
| 48 mo | 33.4% | 13.5% |
| 60 mo | 25.4% | 13.5% |
Checks against the published figure
- Niraparib median: printed 27.5, reconstructed 27.6 pass
- Placebo median: printed 17.3, reconstructed 17.2 pass
- Niraparib events: printed 111, reconstructed 112 pass
- Niraparib n: printed 177, reconstructed 177 pass
- Placebo events: printed 64, reconstructed 64 pass
- Placebo n: printed 88, reconstructed 88 pass
- hazard ratio (direction inferred): printed 0.52, reconstructed 0.529 pass
About these data
Pseudo-IPD reproduces the published curves and numbers at risk; the rows are not real patients. Cite the publication (DOI above) and TrialCurve. The source figure is © the authors (CC BY 4.0); the charts here are redrawn from the reconstruction.
Load these data in R or Python
# R
library(survival)
d <- read.csv("https://trialcurve.com/data/trials/nora-final-overall-survival-1.csv")
survfit(Surv(time, event) ~ arm, data = d)
coxph(Surv(time, event) ~ arm, data = d)
# Python
import pandas as pd
from lifelines import KaplanMeierFitter
d = pd.read_csv("https://trialcurve.com/data/trials/nora-final-overall-survival-1.csv")
for arm, g in d.groupby("arm"):
KaplanMeierFitter().fit(g.time, g.event, label=arm).plot_survival_function()
Suggested citation: eClinicalMedicine. 2024 May 7;72:102629. doi: 10.1016/j.eclinm.2024.102629 doi:10.1016/j.eclinm.2024.102629. Reconstructed data: TrialCurve (2026), https://trialcurve.com/trials/nora-final-overall-survival
Report a problem with these data
Related trials
- SCORES: Overall survival; Overall survival, final analysis
- COPELIA: Overall survival; Progression-free survival
- Chemoradiotherapy ± simultaneous integrated boost in cervical cancer: Overall survival; Pelvic-specific PFS; Progression-free survival (PFS)
- PORTEC-3 (primary analysis): Failure-free survival; Overall survival
- PORTEC-3: Overall survival; Recurrence-free survival
Need reconstructed data for other trials? Upload any Kaplan–Meier figure, or ask about the TrialCurve oncology library.
Reconstruct a figure Browse all trials